sucralose
Small moleculeexperimental
Sucralose is an artificial sweetener and sugar substitute. In the European Union, it is also known under the E number E955. It is produced by chlorination of sucrose, selectively replacing three of the hydroxy groups—in the C1 and C6 positions of the fructose portion and the C4 position of the glucose portion—to give a 1,6-dichloro-1,6-dideoxyfructose–4-chloro-4-deoxygalactose disaccharide. Sucralose is about 600 times sweeter than sucrose, 3 times as sweet as both aspartame and acesulfame potassium, and 2 times as sweet as sodium saccharin. — Wikipedia
Clinical trial activity
34 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00955747)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@H]1Cl- Mol. weight
- 397.64 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSucralose ↗
- ChEMBLCHEMBL3185084 ↗
- ChEMBLCHEMBL2107529 ↗
Also known as
- 1',4',6'-trichloro-1',4,6'-trideoxygalactosucrose
- 1,6-dichloro-1,6-dideoxy-beta-d-fructofuranosyl-4-chloro-4-deoxy-alpha-d-galactopyranoside
- alpha-d-galactopyranoside, 1,6-dichloro-1,6-dideoxy-beta-d-fructofuranosyl 4-chloro-4-deoxy-
- splenda
- splenda
- splenda
- sucralose
- sucralose
- sucralose
- sucralose
- trichlorogalactosucrose
- trichlorogalacto-sucrose
- trichlorosucrose
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997133 | N/A | Sep 1, 2025 | Ciusss de L'Est de l'Île de Montréal |
| NCT07231133 | N/A | May 6, 2025 | Anderson Advanced Ingredients, Metropolitan University |
| NCT05852587 | Phase 1 | May 1, 2024 | Harvard University |
| NCT06094894 | N/A | Jun 1, 2023 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT05575687 | N/A | Nov 30, 2022 | Tate & Lyle, Wageningen University |
| NCT05279183 | N/A | Mar 17, 2022 | St. Claraspital Basel, University of Basel |
| NCT04633811 | N/A | Jan 1, 2022 | The University of Texas, Dallas, University of Alabama, Birmingham |
| NCT04713137 | N/A | Feb 8, 2021 | St. Claraspital Basel, University of Basel |
| NCT04578431 | N/A | Nov 1, 2020 | Aarhus University |
| NCT04185662 | N/A | Dec 1, 2019 | Jiao Tong University, PuNan Hospital, Shanghai, ShiBei Hospital |
| NCT04182464 | N/A | Nov 1, 2019 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT03436277 | Phase 2 | Dec 17, 2018 | University of Guadalajara |
| NCT03716609 | N/A | Oct 23, 2018 | Academia Sinica, Taiwan, Government of Taiwan, Institute of Biomedical Sciences, Academia Sinica, Taipei Veteran General hospital |
| NCT03407079 | Phase 2 | Apr 5, 2018 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT03242434 | Phase 1 | Jan 29, 2018 | GlaxoSmithKline |
| NCT02800707 | N/A | Jan 3, 2017 | University of Minnesota |
| NCT03703141 | N/A | Sep 27, 2016 | Hospital General de México Dr. Eduardo Liceaga |
| NCT02569762 | N/A | Jul 1, 2016 | University of Manitoba |
| NCT05983328 | Phase 1 | May 10, 2016 | Sinew Pharma Inc. |
| NCT02745730 | N/A | Mar 31, 2016 | Leiden University, Unilever |
Showing 20 of 34 trials
Page 1 / 2
Organizations
Research & Development (40)
40 organizations
Page 1 / 2